A platform in which materials and technologies will be developed to stimulate research with so-called organotypic skin, small pieces of cultured skin. The goal of this project is to widely implement these skin models for better skin research and facilitate the development of novel therapeutics for skin diseases.

The Platform for Alternative Skin Tests for sustainable Future science (PAST4FUTURE) is a consortium led by the Radboudumc. This project is carried out together with partners from the Radboud University, VU University Medical Center, Leiden University Medical Center, Association of Cooperating Burns Centers in the Netherlands, CELLnTEC Advanced Cell Systems AG, and TropIQ Health Sciences.


Consortium leader: Prof. Ellen van den Bogaard
Laboratory for Experimental Dermatology
Radboud university medical center

Radboud Institute for Molecular Life Sciences

Follow us:

News and Media…..

PAST4FUTURE’s first on-site consortium meeting

On Friday 20 May, the consortium held its first in-person/partially remote user committee meeting at the Radboudumc, The Netherlands. In total 13 partners attended the meeting, in a great mix of scientists, biotech companies, funding agencies, and societal organizations. It was so nice seeing each other finally 18 months after the project kick-off. In deptsContinue reading “PAST4FUTURE’s first on-site consortium meeting”

11 million euro funding for Dutch research consortium Next Generation Immunodermatology (NGID)

The Dutch Research Council (NWO) has, within the framework of Research along Routes by Consortia (NWA-ORC), awarded the research project Next Generation Immuno-Dermatology (NGID) with a prestigious grant of 11.7 MEuro. NGID is a nationwide, large-scale project to unravel novel biomarkers for six different skin diseases. These biomarkers will drive a high-tech, patient-centric approach inContinue reading “11 million euro funding for Dutch research consortium Next Generation Immunodermatology (NGID)”

‘Such model will enable fundamental biological studies for a better understanding of the aetiology and pathophysiology of psoriasis and aid in novel therapeutic target identification and drug development studies.’

Exp Dermatol (2018) 27(5):512-519.